Hisamitsu Pharmaceutical Co (TSE:4530) Long-Term Capital Lease Obligation : 円0 Mil (As of Nov. 2023)

View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co Long-Term Capital Lease Obligation?

Hisamitsu Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Nov. 2023 was 円0 Mil.

Hisamitsu Pharmaceutical Co's annual Long-Term Capital Lease Obligation declined from Feb. 2022 (円869 Mil) to Feb. 2023 (円750 Mil) and declined from Feb. 2023 (円750 Mil) to Feb. 2024 (円603 Mil).

Hisamitsu Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co Long-Term Capital Lease Obligation Chart

Hisamitsu Pharmaceutical Co Annual Data

Trend

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

130.00

94.00

869.00

750.00

603.00

Hisamitsu Pharmaceutical Co Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															750.00	-	-	-	603.00

Hisamitsu Pharmaceutical Co (TSE:4530) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Hisamitsu Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

HPX:Germany

Address

408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017

Website

http://www.hisamitsu.co.jp

Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines